KALA News and Press, Kala Pharmaceuticals Inc. From 05/07/20

-- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary and Key Secondary Endpoints -- -- EYSUVIS TM NDA Resubmitted on April 30 th ; Potential Approval and Launch Before Year-End -- -- R...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the virtual BofA Securities 2020 Health Care Conference. Mark Iwicki, Chai...

Kala Pharmaceuticals (NASDAQ: KALA ) has resubmitted its U.S. marketing application for Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term treatment of symptoms of dry eye disease. More news on: Kala Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (F...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020. Management will...

One of the trends in the first quarter of 2020 has been the significant underperformance of small-cap equities as a market segment amid the extreme levels of volatility. For context, the iShares Russell 2000 ETF ( IWM ) is down about 25% compared to a 13% decline in the S&P 500 Index ( S...

Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA) today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on March 13, 2020, have exercised a portion of their option to purchase additional shares of common stoc...

Today, we will see why Kala Pharmaceuticals ( KALA ) is an attractive pick in March 2020. Despite the massive selloff across markets due to coronavirus pandemic, the company has managed to post around 100% return on YTD (year-to-date) basis. Company overview Headquartered in Watertown, M...

I am constantly looking to provide valuable information to my readers on how to outperform the market while taking few risks. A very strong strategy to outperform the market is following insider purchases, as literature has proven that this strategy could beat the market by as much as 24.20% p...

Kala Pharmaceuticals ( KALA ) announced that it had achieved positive results from its phase 3 study using EYSUVIS for the treatment of patients with dry eye disease. It had trouble in the past with its first NDA of this drug, because it had received a CRL. Now that the biotech has been ...